𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: A literature review

✍ Scribed by Antonina A. Mikocka-Walus; Deborah A. Turnbull; Nicole T. Moulding; Ian G. Wilson; Jane M. Andrews; Gerald J. Holtmann


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
106 KB
Volume
13
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis


Psychological disorders are highly prevalent in patients with inflammatory bowel disease (IBD). Anxiety and depression are known to independently affect quality of life and may additionally impair quality of life in IBD over and above the IBD itself. Some researchers have further proposed that anxiety and depression may influence the clinical course of IBD. However, despite the potential for anxiety and depression to play an important role in the clinical picture of IBD, there is little prospective well-controlled research in this area. Probably because of this lack of clear data, researchers dispute the actual role of these psychological disorders in IBD, with a number of conflicting opinions expressed. This article reports on a review of the literature in this field. Herein we discuss the five main areas of controversy regarding IBD and the specific psychological comorbidities of depression and anxiety: 1) the relative rate of cooccurrence of these psychological disorders with IBD; 2) the cooccurrence of these psychological disorders with particular phase of IBD; 3) the cooccurrence of these psychological disorders with the specific type of IBD; 4) the rate of these psychological comorbidities compared both to healthy subjects and to other disease states; and 5) the timing of onset of psychological comorbidity with respect to onset of IBD. Methodological weaknesses of the reviewed studies make it impossible to resolve these controversies. However, the results clearly show that anxiety/depression and IBD frequently interact. Given the long-term illness burden patients with IBD face, further prospective, appropriately controlled studies are needed to adequately answer the question of the precise interplay between anxiety/depression and IBD.


πŸ“œ SIMILAR VOLUMES


Depression and anxiety in inflammatory b
✍ Lesley A. Graff; John R. Walker; Charles N. Bernstein πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 142 KB πŸ‘ 1 views

While there has been a great deal of speculation over the years on the importance of emotional factors in inflammatory bowel disease (IBD), it is only in the last decade or so that studies with stronger designs have been available to clarify the nature of this relationship. This review considers rec

Anxiety and depression in patients with
✍ Winfried HΓ€user; Karl-Heinz Janke; Bodo Klump; Andreas Hinz πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 1 views

Background: Studies on anxiety and depression in inflammatory bowel disease (IBD) yielded inconsistent results. We compared anxiety and depression of patients with Crohn's disease (CD) and ulcerative colitis (UC) controlled for sociodemographic and medical variables with age-and sex-matched controls

Association between Helicobacter pylori
✍ Jay Luther; Maneesh Dave; Peter D.R. Higgins; John Y. Kao πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 451 KB πŸ‘ 2 views

Background: Epidemiologic data suggest a protective effect of Helicobacter pylori infection against the development of autoimmune disease. Laboratory data illustrate H. pylori's ability to induce immune tolerance and limit inflammatory responses. Numerous observational studies have investigated the

Lost in translation: Helping patients un
✍ Corey A. Siegel πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 93 KB πŸ‘ 1 views

Patients with inflammatory bowel disease are commonly treated with immunomodulators and biologic therapy. These treatments can be very effective, but are associated with risks of adverse events that need to be discussed with patients. Effectively communicating risks of therapy can be challenging bas

Oral budesonide for the therapy of post-
✍ A. Sidney Barritt IV; Steven L. Zacks; Tara C. Rubinas; Hans H. Herfarth πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 442 KB πŸ‘ 1 views

## Background: The therapy for posttransplant ibd is clinically challenging. patients receiving liver transplants are immunosuppressed to prevent rejection, but via an unknown mechanism develop de novo ibd in spite of receiving some of the same medications used for therapy in traditional ibd. in th